Prospect: information for the patient
Lokelma 5g powder for oral suspension
Lokelma 10g powder for oral suspension
sodium and zirconium silicate
Read this prospect carefully before starting to take this medication, as it contains important information for you.
1.What is Lokelma and what it is used for
2.What you need to know before starting to take Lokelma
3.How to take Lokelma
4.Adverse effects
5.Storage of Lokelma
6.Contents of the package and additional information
Lokelma contains the active ingredient sodium zirconium cyclosilicate.
Lokelma is used to treat hyperkalemia in adults. Having hyperkalemia means that there is a high level of potassium in the blood.
Lokelma reduces high levels of potassium in your body and helps to maintain a normal level. As it passes through the stomach and intestine, Lokelma binds to potassium and both are carried together and eliminated from the body with the feces, reducing the amount of potassium in the body.
Do not take Lokelma:
Warnings and precautions
Follow-up
Your doctor or nurse will check your blood potassium level when you start taking this medicine:
While you are taking Lokelma, consult your doctor or nurse if
Children and adolescents
Do not administer this medicine to children or adolescents under 18 years old, as the effects of Lokelma in children or adolescents are unknown.
Other medicines and Lokelma
Inform your doctor or nurse if you are taking, have taken recently, or may need to take any other medicine.
Lokelmamay affect the way certain medicines are absorbed in your digestive tract. If you are taking any of the followingmedicines, they should be taken 2hours before or after taking Lokelma, otherwise they may not work correctly.
If any of the above situations apply to you (or if you have doubts), speak with your doctor, pharmacist, or nurse before taking this medicine.
Pregnancy and breastfeeding
Pregnancy
Do not use this medicine during pregnancy, as there is no information available on its use during pregnancy.
Breastfeeding
No adverse effects are expected in newborns/breastfed infants, as systemic exposure to Lokelma in lactating mothers is insignificant. Lokelma may be used during breastfeeding.
Driving and operating machinery
The influence of this medicine on your ability to drive and operate machinery is negligible or insignificant.
Lokelma contains sodium
This medicine contains approximately 400mg of sodium (main component of table salt/for cooking) in each 5g dose. This is equivalent to 20% of the recommended daily maximum sodium intake for an adult.
Speak with your pharmacist or doctor if you need Lokelma 5g or more per day for a prolonged period, especially if you have been advised to follow a low-sodium diet.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor again.
How much to take
Initial dose‑to reduce elevated potassium levels to normal:
Maintenance dose‑to maintain potassium levels within the normal range once they have decreased:
If you are on hemodialysis therapy:
How to take this medication
Form of use
If you take more Lokelma than you should
If you take more of this medication than you should, consult a doctor as soon as possible. Do not take it again until you have spoken with a doctor.
If you forget to take Lokelma
If you interrupt treatment with Lokelma
Do not reduce the dose of this medication or stop taking it without speaking with the doctor who prescribed it. If you do, your potassium levels in the blood may increase again.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medications, this medication may produce adverse effects, although not everyone will experience them.
Inform your doctor or nurse if you experience any of the following adverse effects:
Frequent (may affect up to 1 in 10 people):
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through thenational notification system included in theAppendix V.By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister pack after “CAD/EXP”. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through the drains or in the trash. Ask your pharmacist how to dispose of the packaging and the medication that you no longer need. In this way, you will help protect the environment.
Composition of Lokelma
The active ingredient is sodium and zirconium cyclamate.
Lokelma 5g powder for oral suspension
Each sachet contains 5g ofsodium and zirconium cyclamate.
Lokelma 10g powder for oral suspension
Each sachet contains 10g ofsodium and zirconium cyclamate.
This medicine does not contain any other components.
Appearance of the product and contents of the pack
The powder for oral suspension is a white to grey powder. It is presented in a sachet.
Lokelma 5g powder for oral suspension
Each sachet contains 5g of powder.
Lokelma 10g powder for oral suspension
Each sachet contains 10g of powder.
The sachets are presented in a box with 3 or 30sachets.
Only some pack sizes may be marketed.
Marketing Authorisation Holder
AstraZeneca AB
SE‑151 85 Södertälje
Sweden
Responsible for manufacturing
AstraZeneca AB
Gärtunavägen
SE‑152 57 Södertälje
Sweden
For more information about this medicine, please contact the local representative of the marketing authorisation holder:
Belgium/Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 11 | Lithuania UAB AstraZenecaLithuania Tel: +370 5 2660550 | |
Bulgaria AstraZeneca EAD Tel: +359 24455000 | Luxembourg/Luxembourg AstraZeneca S.A./N.V. Tél/Tel: +32 2 370 48 11 | |
Czech Republic AstraZeneca Czech Republic s.r.o. Tel:+420 222 807 111 | Hungary AstraZeneca Kft. Tel.: +36 1 883 6500 | |
Denmark AstraZeneca A/S Tlf: +45 43 66 64 62 | Malta Associated Drug Co. Ltd Tel: +356 2277 8000 | |
Germany AstraZeneca GmbH Tel: +49 40 809034100 | Netherlands AstraZeneca BV Tel: +31 79 363 2222 | |
Estonia AstraZeneca Tel: +372 6549 600 | Norway AstraZeneca AS Tlf: +47 21 00 64 00 | |
Greece AstraZeneca A.E. Τηλ: +30 210 6871500 | Austria AstraZeneca Österreich GmbH Tel: +43 1 711 31 0 | |
Spain AstraZeneca Farmacéutica Spain, S.A. Tel: +34 91 301 91 00 | Poland AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22245 73 00 | |
France AstraZeneca Tél: +33 1 41 29 40 00 | Portugal AstraZeneca Produtos Farmacêuticos, Lda. Tel: +351 21 434 61 00 | |
Croatia AstraZeneca d.o.o. Tel: +385 1 4628 000 | Romania AstraZeneca Pharma SRL Tel: +40 21 317 60 41 | |
Ireland AstraZeneca Pharmaceuticals (Ireland) Ltd Tel: +353 1609 7100 | Slovenia AstraZeneca UKLimited Tel: +386 1 51 35 600 | |
Iceland Vistor hf. Sími: +354 535 7000 | Slovakia AstraZeneca AB, o.z. Tel: +421 2 5737 7777 | |
Italy AstraZeneca S.p.A. Tel: +39 02 00704500 | Finland AstraZeneca Oy Puh/Tel: +358 10 23 010 | |
Cyprus AlkêtoPharmaceuticalsLtd Τηλ: +357 22490305 | Sweden AstraZeneca AB Tel: +46 8 553 26000 | |
Lithuania SIA AstraZeneca Latvija Tel: +371 67377100 | United Kingdom (Northern Ireland) AstraZeneca UK Ltd Tel: +44 1582 836836 |
Last update of this leaflet:
Other sources of information
Further information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.